© Reuters. FILE PHOTO: A logo on the Sanofi exhibition space at the Viva Technology conference dedicated to innovation and startups at Porte de Versailles exhibition center in Paris, France June 15, 2022. REUTERS/Benoit Tessier
PARIS (Reuters) – Sanofi (NASDAQ:)’s COVID-19 vaccine candidate, which is modelled on the virus’s Beta antigen, delivered 72% efficacy in adults against the Omicron strain, the French drugmaker said on Friday, citing data gathered in a study.
“Sanofi-GSK’s vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation,” the firm, which is developing the vaccine jointly with Britain’s GSK, said in a statement.
The new data supporting its booster vaccine will be submitted to regulatory authorities, Sanofi added, reiterating its plan to start marketing its jab later this year.